ロード中...
Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice
Diabetic neuropathy (DN) is a common complication of diabetes. Currently, there is no drug treatment to prevent or slow the development of DN. Rosiglitazone (Rosi) is a potent insulin sensitizer and may also slow the development of DN by a mechanism independent of its effect on hyperglycemia. A two...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Endocrine Society
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2582925/ https://ncbi.nlm.nih.gov/pubmed/18583417 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/en.2008-0869 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|